High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 7, 2010, Pages 1276-1280

  Bate, John P ^a   Colman, Anton J ^a   Frost, Peter J ^a   Shaw, David R ^a   Harley, Hugh A J ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

chronic hepatitis C; late relapse; prisoners; reinfection

Indexed keywords

INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; ANTIVIRUS AGENT; VIRUS RNA;

ADULT; ARTICLE; CLINICAL PRACTICE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HOSPITAL INFORMATION SYSTEM; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENTAL DISEASE; PREVALENCE; PRIORITY JOURNAL; PRISONER; REINFECTION; RELAPSE; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; AUSTRALIA; BLOOD; COMPLICATION; DRUG COMBINATION; DRUG USE; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; RECURRENT DISEASE; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE; TIME; TRANSMISSION; CHRONIC HEPATITIS C; DRUG DOSE REDUCTION; RECURRENCE RISK;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; DRUG USERS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; PREVALENCE; PRISONERS; RECURRENCE; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; SOUTH AUSTRALIA; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77953985349     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06295.x     Document Type: Article

References (31)

1. Razali K, Thein HH, Bell J et al. Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol Depend. 2007 91 : 228 235.
2. Robotin MC, Copland J, Tallis G et al. Surveillance for newly acquired hepatitis C in Australia. J. Gastroenterol. Hepatol. 2004 19 : 283 288.
3. Miller ER, Bi P, Ryan P. Hepatitis C virus infection in South Australian prisoners: seroprevalence, seroconversion, and risk factors. Int. J. Infect. Dis. 2009 13 : 201 208.
4. Hellard ME, Hocking JS, Crofts N. The prevalence and the risk behaviours associated with the transmission of hepatitis C virus in Australian correctional facilities. Epidemiol. Infect. 2004 132 : 409 415.
5. Farley J, Vasdev S, Fischer B, Haydon E, Rehm J, Farley TA. Feasibility and outcome of HCV treatment in a Canadian federal prison population. Am. J. Public Health 2005 95 : 1737 1739.
6. Allen SA, Spaulding AC, Osel AM, Taylor LE, Cabral AM, Rich JD. Treatment of chronic hepatitis C in a state correction facility. Ann. Intern. Med. 2003 138 : 187 190.
7. Maru DS, Bruce RD, Basu S, Altice FL. Clinical outcomes of hepatitis C treatment in a prison settting: feasibility and effectiveness for challenging treatment populations. Clin. Infect. Dis. 2008 47 : 952 961.
8. Strock P, Mossong J, Hawotte K, Arendt V. Access to treatment of hepatitis C in prison inmates. Dig. Dis. Sci. 2009 54 : 1325 1330.
9. Batey RG, Jones T, McAllister C. Prisons and HCV: a review and a report on an experience in New South Wales Australia. Int. J. Prison Health 2008 4 : 156 163.
10. Chew KW, Allen SA, Taylor LE, Rich JD, Feller E. Treatment outcomes with pegylated interferon and ribavirin for male prisoners with chronic hepatitis C. J. Clin. Gastroenterol. 2009 43 : 686 691.
11. Sterling RK, Hofmann CM, Luketic VA et al. Treatment of chronic hepatitis C virus in the Virginia Department of Corrections: can compliance overcome racial differences to response? Am. J. Gastroenterol. 2004 99 : 866 872.
12. Spaulding AC, Welnbaum CM, Lau DTY et al. A framework for management of hepatitis C in prisons. Ann. Intern. Med. 2006 144 : 762 769.
13. Tan JA, Joseph TA, Saab S. Treating hepatitis C in the prison population is cost-saving. Hepatology 2008 48 : 1387 1395.
14. Medew J. Prisoners Go Untreated as Hepatitis C Sweeps Jails. Cited 17 Feb 2009. Available from URL: http://www.theage.com.au/national/prisoners-go- untreated-as-hepatitis-c-sweeps-jails-20081228-767n.html
15. George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009 49 : 729 738.
16. Maylin S, Martinot-Peignoux M, Ripault M-P et al. Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody. Liver Int. 2009 29 : 511 517.
17. Swain MG, Lai M-Y Shiffman ML et al. Durable sustained virological response after treatment with peginterferon α-2a (Pegasys®) alone or in combination with ribavirin (Copegus®): 5-year follow-up and the criteria of a cure. J. Hepatol. 2007 46 : S3.
18. Maylin S, Martinot-Peignoux M, Moucari R et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008 135 : 821 829.
19. McHutchison JG, Poynard T, Esteban-Mur R et al. Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology 2002 35 : 688 693.
20. Ghany MG, Strader DB, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009 49 : 1335 1374.
21. Forrest G, Douglas J. The challenges and benefits of hepatitis C treatment in custody. J. Gastroenterol. Hepatol. 2008 23 : A347.
22. Mellor K, Arachchi NJ, Watson K, Tuck E, Bell SJ, Desmond PV. Treating hepatitis C in prison: experience in Victoria. J. Gastroenterol. Hepatol. 2008 23 : A372.
23. Lewis RM, Chilman JL, Dempsey MG et al. A collaborative approach to hepatitis C education, testing and treatment at Lotus Glen Correctional Centre in far north Queensland. J. Gastroenterol. Hepatol. 2008 23 : A384.
24. Dalgard O. Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clin. Infect. Dis. 2005 40 : S336 338.
25. Grebely J, Matthews GV, White PA et al. Incidence and risk factors for HCV reinfection and superinfection in individuals treated for acute/early chronic HCV infection. J. Gastroenterol. Hepatol. 2008 23 : A343.
26. Mehta SH, Cox A, Hoover DR et al. Protection against persistence of hepatitis C. Lancet 2002 359 : 1478 1483.
27. Backmund M, Meyer K, Edlin BR. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin. Infect. Dis. 2004 39 : 1540 1543.
28. Marcellin P, Boyer N, Gervais A et al. Long-term histological improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann. Intern. Med. 1997 127 : 875 881.
29. Veldt BJ, Saracco G, Boyer N et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 2004 53 : 1504 1508.
30. Chang GL, Rawlings L, Turra M et al. Phylogenetic analysis of hepatitis C infection in South Australia. J. Clin. Virol. 2006 36 : 151.
31. Roberts SK, Weltman MD, Crawford DH et al. Chariot Study Group. Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial. Hepatology 2009 50 : 1045 1055.